Avadel PharmaceuticalsAVDL
13F holders, Q2 2024 (June 30)10holders −109
2new positions
19sold out
$14.06avg. 13F price*
At the end of Q2 2024, 10 institutions reported holding Avadel Pharmaceuticals plc (AVDL) in their 13F filings, down 109 from Q1 2024. 2 opened new positions and 19 sold out. The largest holders were Vivo Capital, LLC ($55.8M), Tri Locum Partners LP ($16.7M) and MPM Bioimpact LLC ($11.0M).
- Company
- Avadel Pharmaceuticals plc
- CUSIP
- 05337M104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $141K |
| Exits | 19 | $177.8M |
All 13F filers, Q1 2024 → Q2 2024: 10,062 shares bought and 10,611,202 shares sold, net −10,601,140 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Vivo Capital, LLC | 5.16% | No change | 3,972,099 | $55.8M |
| Tri Locum Partners LP | 4.23% | Add +0.0% | 1,189,518 | $16.7M |
| MPM Bioimpact LLC | 1.71% | Reduce -10.1% | 783,242 | $11.0M |
| Knoll Capital Management, LLC | 5.68% | No change | 600,000 | $8.4M |
| Knott David M Jr | 1.87% | No change | 333,000 | $4.7M |
| Schulhoff & Co. Inc. | 0.87% | No change | 137,000 | $1.9M |
| Ameritas Investment Partners, Inc. | 0.00% | New | 9,055 | $127K |
| 1620 Investment Advisors, Inc. | 0.01% | New | 1,000 | $14K |
| Cwm, LLC | 0.00% | No change | 99 | $1K |
| Huntington National Bank | 0.00% | No change | 1 | $16 |
"% of holder's portfolio" is AVDL's weight in each manager's 13F, not the share of Avadel Pharmaceuticals plc the manager owns.